Compare VanEck Gold Miners ETF (GDX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs McKesson Corporation — how do they compare? VanEck Gold Miners ETF trades at $88.9 (market cap $25.65B), while McKesson Corporation trades at $930.2 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.2× VanEck Gold Miners ETF's market cap, and McKesson Corporation pays a 0.4% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and McKesson Corporation for 74 Days on average.
| GDX | MCK | |
|---|---|---|
Market Cap | $25.65B | $108.46B |
Volume | 16,534,046 | 712,607 |
52-Week High | $115.84 | $995.69 |
52-Week Low | $68.28 | $725.17 |
Typical Hold Time | 76 Days | 74 Days |
Sector | — | Health |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.31, up 4.51% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces headwinds from rising interest rates pressuring dividend stocks and a recent sell-off in metals. Support levels are clustered between $84 and $86, while resistance sits near $87 to $89. Recent news highlights institutional selling by firms like Allworth Financial and HB Wealth Management, though Ameritas Advisory Services increased its stake.
The outlook for GDX is cautious due to bearish technicals and macroeconomic pressures on gold miners. Opportunities exist if gold prices rebound, but risks include persistent rate hikes and volatility in commodity markets. Investors should weigh the ETF's leverage to gold against operational risks in the mining sector.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
